GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain

Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine
Cheng Hsiang YaoShiaw-Pyng Wey

Abstract

We report herein the Good Manufacturing Practice (GMP)-compliant automated synthesis of (18)F-labeled styrylpyridine, AV-45 (Florbetapir), a novel tracer for positron emission tomography (PET) imaging of beta-amyloid (Abeta) plaques in the brain of Alzheimer's disease patients. [(18)F]AV-45 was prepared in 105 min using a tosylate precursor with Sumitomo modules for radiosynthesis under GMP-compliant conditions. The overall yield was 25.4+/-7.7% with a final radiochemical purity of 95.3+/-2.2% (n=19). The specific activity of [(18)F]AV-45 reached as high as 470+/-135 TBq/mmol (n=19). The present studies show that [(18)F]AV-45 can be manufactured under GMP-compliant conditions and could be widely available for routine clinical use.

References

Mar 29, 2000·JAMA : the Journal of the American Medical Association·D J Selkoe
Nov 17, 2004·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Nicolaas P L G VerhoeffSylvain Houle
Aug 2, 2006·Journal of Geriatric Psychiatry and Neurology·Gary W Small
May 15, 2007·Neurobiology of Aging·Anton ForsbergAgneta Nordberg
Apr 18, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Michel KooleKoen Van Laere
Jun 6, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Svante NybergLars Farde
Jul 21, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Natalie NelissenRik Vandenberghe

❮ Previous
Next ❯

Citations

Jan 25, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Ing-Tsung HsiaoKun-Ju Lin
Feb 16, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Ing-Tsung HsiaoKun-Ju Lin
Aug 3, 2011·Bioconjugate Chemistry·Christopher A D'SouzaDavid M Goldenberg
Jun 15, 2013·Beilstein Journal of Organic Chemistry·Todd J EckroatSylvie Garneau-Tsodikova
Dec 6, 2014·Alzheimer's Research & Therapy·Victor L VillemagneTakeshi Iwatsubo
Apr 29, 2015·EJNMMI Research·Behrooz H YousefiHans-Jürgen Wester
Dec 3, 2016·Journal of Alzheimer's Disease : JAD·Ann-Marie WaldronSteven Staelens
Nov 29, 2013·Journal of Labelled Compounds & Radiopharmaceuticals·Kazutaka HayashiKazuhiro Takahashi
Nov 29, 2013·Journal of Labelled Compounds & Radiopharmaceuticals·N Scott MasonWilliam E Klunk
Nov 8, 2019·Journal of Labelled Compounds & Radiopharmaceuticals·Lifang ZhangHank F Kung
Nov 7, 2019·European Journal of Nuclear Medicine and Molecular Imaging·Sylvain AuvityBruno Stankoff
Oct 16, 2018·Journal of Alzheimer's Disease : JAD·Yi-Ching WengChin-Chang Huang
Jul 10, 2019·Contrast Media & Molecular Imaging·Min ZhangFabien Chauveau
Mar 25, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Julie OttoySteven Staelens
Jun 15, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Steven DeleyeSteven Staelens
Aug 10, 2021·Frontiers in Aging Neuroscience·Adrian L OblakBruce T Lamb

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.